Revolution Medicines, Inc. <RVMD.O>: Oppenheimer raises target price to $230 from $195
RVMD•Related News
Sonoma Pharmaceuticals Q1 revenue rises on US growth
SNOA•
Datadog forecasts slower quarterly revenue growth, shares tumble
DDOG•
Aurora Innovation to host virtual retail investor town hall with CEO, CFO
AUR•
Warner Bros' revenue disappoints on soft ad sales, weak box-office performance
WBD•
Insulet Corporation <PODD.O>: Benchmark cuts target price to $185 from $250
PODD•